- Home
- RDHL vs PRPO Comparison
RDHL vs PRPO Comparison
Compare RDHL & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- PRPO
- Stock Information
- Founded
- RDHL 2009
- PRPO N/A
- Country
- RDHL Israel
- PRPO United States
- Employees
- RDHL N/A
- PRPO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- RDHL Health Care
- PRPO Industrials
- Exchange
- RDHL Nasdaq
- PRPO Nasdaq
- Market Cap
- RDHL 4.3M
- PRPO 17.1M
- IPO Year
- RDHL N/A
- PRPO N/A
- Fundamental
- Price
- RDHL $2.18
- PRPO $14.85
- Analyst Decision
- RDHL
- PRPO
- Analyst Count
- RDHL 0
- PRPO 0
- Target Price
- RDHL N/A
- PRPO N/A
- AVG Volume (30 Days)
- RDHL 17.8K
- PRPO 17.6K
- Earning Date
- RDHL 08-28-2025
- PRPO 08-12-2025
- Dividend Yield
- RDHL N/A
- PRPO N/A
- EPS Growth
- RDHL N/A
- PRPO N/A
- EPS
- RDHL N/A
- PRPO N/A
- Revenue
- RDHL $8,042,999.00
- PRPO $20,029,000.00
- Revenue This Year
- RDHL $381.91
- PRPO N/A
- Revenue Next Year
- RDHL N/A
- PRPO N/A
- P/E Ratio
- RDHL N/A
- PRPO N/A
- Revenue Growth
- RDHL 23.17
- PRPO 26.67
- 52 Week Low
- RDHL $1.71
- PRPO $3.90
- 52 Week High
- RDHL $20.28
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- RDHL 65.22
- PRPO 68.17
- Support Level
- RDHL $2.00
- PRPO $15.00
- Resistance Level
- RDHL $2.08
- PRPO $16.89
- Average True Range (ATR)
- RDHL 0.09
- PRPO 1.13
- MACD
- RDHL 0.03
- PRPO 0.33
- Stochastic Oscillator
- RDHL 97.73
- PRPO 67.99
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.